CAR T-cells are an exciting new therapeutic area in multiple myeloma (MM). Here, the experts discuss the current landscape of this novel therapy in MM, including exploratory targets; with not all convinced that BCMA is the optimal target. Furthermore, the cost vs. value of CAR T-cell therapy is explored, with several types of payment systems proposed. Chaired by David Siegel, MD, PhD, of the John Theurer Cancer Center, Hackensac, NJ, the dicussion includes Andrew Spencer, MBBS, FRACP, FRCPA, DM, of Alfred Hospital, Monash University, Melbourne, Australia, and Ravi Vij, MD, MBA, of Washington University Medical School, St. Louis, MO. This discussion took place at the Myeloma 2018 meeting, held in San Diego, CA.